Current Clinical Trials | ECHO Associates

Current Trials

Genetic Risk Assessment

ECHO Open to Accrual Clinical Trials

Updated: 12/18/2025

Colorectal

Metastatic

(Janssen) Origami 61186372COR3002
A randomized, Open-label Phase 3 study of Amivantamab + Folfiri Versus Cetuximab/Bevacizumab + Folfiri in participants with KRAS/NRAS and BRAF wild-type recurrent, Unresectable or Metastatic Colorectal Cancer who have received prior chemotherapy

WO42758 / INTRINSIC
A Phase I/Ib Global, Multicenter, Open-Label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC) ***Divarasib, Bevacizumab and Folfox is the only arm opened***

Lung

V940-009 (Merck)
A Phase 3 Randomized Double-Blind Study of Adjuvant Pembrolizumab with or without V940 in Participants with Resectable Stage II to IIIB (N2) NSCLC not achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum-based Doublet Chemotherapy (INTerpath-009).

First Line Metastatic:

Mirati 849-007
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced non-Small Cell Lung Cancer with KRAS G12C Mutation

OSE210C302 (Artemia)
A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to immune checkpoint inhibitor (ICI)-Artemia study

Lymphoma/Leukemia

BeiGene BGB-11417-303
A Phase 3 Randomized, Open-Label, Multicenter Study of Sontrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients with
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

MK-1026-011 (BELL WAVE-011)
A Phase 3, Randomized Study to Compare Nemtabrutinib versus comparator (Investigator’s choice of Ibrutinib or Acalabrutinib) in participants with untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Supportive Care

 TP-CA-002 Tempus Gemini NSCLC Surveillance Study
A longitudinal multiomic biomarker profiling study of patients with Non-Small Cell Lung Cancer (NSCLC)
 
TP-CA-007 Tempus Aries
A Biobank Registry Platform Study in Oncology



For more information on clinical trials contact: Dr. Spiro Curis scuris@echoct.com /(860) 886-8362 

To learn about phases of trials and what it means to participate, click here.